Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

The trial evaluated treatment responses in patients who were virologically suppressed, switching from a multi-tablet regimen ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Johnson & Johnson and Legend Biotech are said to have withdrawn an abstract originally planned for next month’s Amer | “At this point, the abstract was withdrawn in alignment with the authors, and we ...